In Galway, Ireland on December 11, 2018, Shanghai MicroPort^® CardioFlow Medtech Co., Ltd. (hereinafter referred to as “MicroPort^® CardioFlow”) announced that the first patient enrollment was completed in Europe for the project of pre-market clinical research on its self-developed VitaFlow^® II Transcatheter Aortic Valve and Recyclable Delivery System (hereinafter referred to as “VitaFlow™ II System”) (“VITALE” project for short).

Shanghai, China - VitaFlow^® Transcatheter Aortic Valve and Delivery System ("VitaFlow^®"), in-house developed by MicroPort CardioFlow has been admitted into the "Green Path" by the China Food and Drug Administration ("CFDA"), a special fast-track procedure for innovative medical devices to gain CFDA approval.

Suzhou, China – From March 22 to March 25, MicroPort^® Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort^® CardioFlow"), a wholly owned subsidiary of Shanghai MicroPort^® Medical (Group) Co., Ltd. ("MicroPort^®"), attended CIT 2018 and released the one-year clinical outcome of VitaFlow^® Transcatheter Aortic Valve and Delivery System ("VitaFlow^®").